Analysts Offer Insights on Healthcare Companies: iCAD (ICAD), Mustang Bio (MBIO) and Cerus (CERS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on iCAD (ICAD – Research Report), Mustang Bio (MBIO – Research Report) and Cerus (CERS – Research Report).

iCAD (ICAD)

In a report released yesterday, Marie Thibault from BTIG maintained a Buy rating on iCAD, with a price target of $3.00. The company’s shares closed last Tuesday at $1.73.

According to TipRanks.com, Thibault is a 1-star analyst with an average return of -0.9% and a 36.4% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Irhythm Technologies.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for iCAD with a $3.00 average price target, representing a 71.4% upside. In a report released yesterday, Craig-Hallum also assigned a Buy rating to the stock.

See today’s best-performing stocks on TipRanks >>

Mustang Bio (MBIO)

BTIG analyst Justin Zelin maintained a Buy rating on Mustang Bio yesterday and set a price target of $8.00. The company’s shares closed last Tuesday at $1.06.

According to TipRanks.com, Zelin is a 5-star analyst with an average return of 27.8% and a 48.7% success rate. Zelin covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals, Poseida Therapeutics, and Viking Therapeutics.

Currently, the analyst consensus on Mustang Bio is a Moderate Buy with an average price target of $8.00.

Cerus (CERS)

In a report released yesterday, Mark Massaro from BTIG reiterated a Hold rating on Cerus. The company’s shares closed last Tuesday at $2.14.

According to TipRanks.com, Massaro is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -15.5% and a 29.7% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Adaptive Biotechnologies, Akoya Biosciences, and BioNano Genomics.

Cerus has an analyst consensus of Moderate Buy, with a price target consensus of $6.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ICAD:

• iCAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results
• iCAD highlights scientific presentations at ECR annual meeting
• iCAD Highlights Promising Clinical Data Demonstrating Ability to Reduce Breast Interval Cancer Rates and Decrease Recall Rates at ECR 2024; Showcases Additional Platform Offerings
• iCAD expands Board of Directors with the appointment of Dr. Hedvig Hricak, MD, PhD, (Dr.h.cᵐ)
• iCAD appoints Hricak to board of directors